SCHEMBL15946356

SCHEMBL15946356

CC(C)(C)NS(=O)(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 2/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
MAPK1 P28482 1/20 0.56
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CYP19A1 P11511 1/20 0.53
LMNA P02545 2/20 0.52
PTGES2 Q9H7Z7 1/20 0.50
HSD11B1 P28845 1/20 0.49
OXTR P30559 1/20 0.49
AVPR1A P37288 1/20 0.49
MMP1 P03956 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
HPGD P15428 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12054697 0.84 CA1 (0.53) SMN1; SMN2MAPTCYP2C9CA1CA2
SCHEMBL12169369 0.84 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL14675663 0.81 MMP1 (0.51) ALDH1A1SMN1; SMN2MAPTCA1CA2
SCHEMBL25506472 0.81 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL29213152 0.81 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL2371994 0.80 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2MAPTCA1CA2
SCHEMBL3834643 0.80 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2MAPTCYP3A4CYP2C9
SCHEMBL13588309 0.79 CA1 (0.56) SMN1; SMN2MAPTCYP2C9CA1CA2
SCHEMBL16477696 0.79 CA1 (0.66) SMN1; SMN2MAPTCA1CA2LMNA
SCHEMBL3071850 0.79 KIF11 (0.50) CA1CA2CYP19A1PTGES2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654802-B2 Indoline derivatives and method for using and producing the same ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSIT (US) 2020-05-19 US disclosed
US-20190135746-A1 INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSITY OF ARIZONA 2019-05-09 US disclosed
US-9464064-B2 HCV helicase inhibitors and methods of use thereof UNIVERSITY OF KANSAS (US) 2016-10-11 US disclosed
US-20140227225-A1 HCV Helicase Inhibitors and Methods of Use Thereof UWM RESEARCH FOUNDATION, INC. (US) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140227225-A1 HCV Helicase Inhibitors and Methods of Use Thereof DHX15, DDX5, DHX35 ALDH1A1 1138/4885SMN1; SMN2 3980/4885MAPT 2466/4885
US-10654802-B2 Indoline derivatives and method for using and producing the same IDO1, IDO2, MMP1 ALDH1A1 161/4885SMN1; SMN2 1391/4885MAPT 1971/4885
US-20190135746-A1 INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME IDO1, INMT, MMP1 ALDH1A1 295/4885SMN1; SMN2 2017/4885MAPT 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.